Moreover, OncoRibo-68 score varied substantially by breast cancer subtype—with particularly high levels in the more aggressive HER2+ and Basal subtypes—and by Nottingham histological grade (G1 vs. G2 vs. G3), suggesting that upregulated RiBi might underlie more advanced tumor phenotypes (Figure 4D,E). This evidence concerns the gene ERBB2 and breast carcinoma.